# 2020 Marker Analysis of Neurology and Brain Disorders April 20-21, 2020 at Bangkok, Thailand

#### Alireza Heidari

Director, Faculty of Chemistry, BioSpectroscopy Core Research Laboratory, California South University (CSU), Irvine, California, USA, E-mail: <a href="mailto:Scholar.Researcher.Scientist@gmail.com">Scholar.Researcher.Scientist@gmail.com</a>

This estimated market analysis is based on probability of approval and sales of products in late stage development, demographic trends and marketing of product. Emerging markets once again helps to boost revenues. CNS therapeutics comprises approximately 15% of total pharmaceutical sales, nearly \$30 billion worldwide. Estimated annual economic costs of anxiety disorders, depression, and schizophrenia are \$47 billion, \$44 billion, and \$33 billion per year approximately. The goal of this session is to understand the market Value & Growth of Neurology Drugs, Current economics cost of clinical research and development.

The key factors contributing to the growth of the global neurology devices market are increasing incidences of neurological disorders such Alzheimer's disease, ischemic stroke, multiple sclerosis, brain cancer, and other such traumas to the brain. Additionally, as a geriatric population is growing, the global neurology devices market is also witnessing a huge encouragement. As most patients are opting for use of neurology devices overuse of drugs due to no side effects and better effectiveness. However, poor reimbursement policies, tough taxation policies in the US and Europe are few factors that are holding back this market.

The hyperbolic government funding in <u>neurology</u> analysis Associate in nursing an ever-growing demand for analysis targeted on drug discovery for development of novel therapies in medicine disorders square measure driving the expansion of neurology market.

The global marketplace for <u>psychotic</u> sickness is anticipated to grow at a slow rate throughout the forecast amount. The slow rate is attributed primarily to the loss of patent exclusivity of branded medicine and therefore the emergence of generic medicine.

Manufacturers of branded medicine square measure probably to expertise a decline in sales revenue thanks to the penetration of low-priced generic medicine within the market, which is likely to impact the growth of the market for antipsychotic drugs.

The provisional results of the European countries which receive grants through the Framework Programme Horizon 2010 has been published, H2010 is the instrument that manages the funding of technological Research, Development and Innovation activities in Europe. For the period 2014-2020, the programme counts with a budget for grants of 74.828 million euros, from which, for the moment 1.933,8 million have been obtained by Spanish entities.

This means that Spain obtains a return of 9.8% EU-28, being thus in fourth position in the ranking by countries, considering the total grant received. The first positions are taken by Germany, UK and France.

These provisional results are very positive. The Centro para el Desarrollo Tecnológico Industrial (CDTI), even calls them "magnificent", since they surpass both the outcome obtained in the whole seventh Framework Programme (8,3% UE-28) and the objectives laid out for the whole H2020 (9,5%).

### **Distribution of the grants**

The main beneficiaries of European grants are companies, with 38.2% of the funding obtained by the country. The rest is divided amongst universities (19.5%), public research centres (11.4%), research associations (11%), technological centres (10%), public administrations (5.8%), associations (4%) and European bodies (0.2%).

The Autonomous Community with a larger with a greater volume of funds so far is Catalonia, with 28.6%, followed by Comunidad de Madrid (25.1%) and, at a certain distance, the Basque country (15.7%).

# **Study Coverage**

The scope of this report is broad and covers therapeutics used in the treatment of neurological disorders.

The report highlights the present and future market potential of neurology medicines and provides a close analysis of the competitive setting, regulations, epidemiology of neurological diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market.

#### **Brain Health Devices Market**

Brain Health devices are utilized as a part of the treatment of neurological disorders, for example, Alzheimer infection and different dementia, epilepsy, cerebrovascular diseases, including stroke, headache, and another migraine issue, Parkinson's sickness, multiple sclerosis, neuroinfections, mind tumors, horrible disarranges of the sensory system because of head injury and neurological issue because of ailing health. Neurological scatters may likewise happen because of different contaminations, for example, viral disease (Zika infection), bacterial disease (Neisseria meningitides), and parasitic contamination (Cryptococcus). As per the World Health Organization (WHO), in 2016, around 450 a great many individuals were influenced by neurological scatters over the world. Around 50 million individuals were accounted for to experience the ill effects of epilepsy over the globe and more than 6 million individuals kick the bucket because of a stroke every year. Brain health devices, for example, CT filter, MRI, EEG, MEG, Transcranial Doppler (TCD) gadgets are generally used to screen mind movement.

# Rising commonness of Alzheimer's Ailment is relied upon to support market development


The central point adding to the development of the brain health devices market is the rising number of Alzheimer's cases. For example, According to the Alzheimer's Association, in 2017, more than 5 million individuals are assessed to experience the ill effects of Alzheimer's malady, which is likewise answered to be

# Market Analysis-2020

the 6th driving reason for death in the U.S. Besides, developing geriatric populace, rising number of horrendous mind damage cases, and uncontrolled headways in innovation, for example, brain biomarkers, quality treatment, undifferentiated cell treatment and keen cerebrum prosthetics are adding to development of the <u>cerebrum</u> wellbeing gadgets showcase. Moreover, finding and treatment neurodegenerative disorders through the microbiome and neuroimaging methods additionally enlarge showcase development. Notwithstanding, high expenses of these gadgets are in charge of impending business sector development.

# The report includes:

- Analyses of the global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2024
- Historical background on neurological disorders and therapeutics, growing prevalence of neurological disorders, increasing research and development activities regarding neurology research, and analysis of the factors influencing the market
- Quantitative analysis of the neurology therapeutics market covering Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, <u>Autism Disorders</u>, and <u>Brain</u> Tumor Diseases.



# **Reasons for Doing this Study**

Global neurology market comprises of various therapeutics used for the treatment of different neurological disorders. The biopharmaceutical companies are investing significantly in the development of innovative therapeutics for the treatment of neurological disorders. Government organizations square measure funding analysis and development activities associated with neurology analysis. These factors are impacting the neurology market positively coupled with the growing prevalence of neurological disorders.

New approaches for the treatment of neurology related indications were pursued by pharmaceutical companies. This new drug with a completely unique mechanism of action or improved delivery system can offer a robust new choice to presently prescribed neurology medicines.

The global neurology market is growing thanks to an increase within the aging population, growing awareness relating to mental and neurologic sickness, increasing insurance reforms and constant analysis and development in neurology by pharmaceutical companies.